2020-06-15
It is with great pleasure to welcome Pål Falck as a CBO for Oncorena, starting September 1, 2020. Pål brings a breadth of relevant experience and competence to strengthen our leadership in time for the exciting next development steps of Oncorena.
Pål joins us from Arctic Securities AS, Oslo where is was en Equity Research Analyst covering Healthcare. Before that he has been with Pfizer and AstraZeneca in medical assignments, including Medical Director and Scout for external opportunities, covering Oncology and other therapeutic areas.
Pål is trained as a pharmacist from University of Oslo and he has a Ph.D. in an area of great relevance to Oncorena, – pharmacokinetics and renal transplantation. He has also a degree as Executive Master of Management. BI, from Norwegian Business School.
Please, join me in congratulating Pål to his new appointment!
Lars Grundemar, M.D., Ph.D.
Chief Executive Officer
Oncorena AB
2022-02-01
Oncorena today announced the initiation of the Phase I-II clinical trial of the first-in-class compound or…
Read more2021-12-23
Oncorena, developing a potential breakthrough therapy for advanced renal cancer, receives a capital inject…
Read more2021-03-01
Oncorena, dedicated to developing a unique and potential breakthrough therapy for metastatic renal cancer,…
Read more